Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has strengthened its balance sheet with the receipt of a A$3.67 million income tax refund from the Australian Taxation Office (ATO), adding further non-dilutive funding as the company advances its synthetic anti-infective pipeline toward key Phase 3 clinical milestones.
The refund relates to the financial year ended June 30, 2025, and comprises A$3.57 million in overseas research and development expenditure, plus A$95,826 in interest paid by the ATO.
Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the critical and precious metals developer, said record gold prices and a tightening uranium market underpinned a strong outlook, after a year of financing left it with the capital to reshape its portfolio.
The company raised more than £15 million during 2025, using the balance sheet to pivot towards a South African gold and power business and a spread of US uranium claims.
Valereum PLC (AQSE:VLRM, FRA:6TJ, OTCQB:VLRMF), the Aquis-listed company targeting the tokenised digital markets sector, used its full-year results to mark its shift from development into commercial operations, with its regulated trading platform now generating revenue.
VLRM Markets, the group's operating subsidiary, launched during the year as a licensed digital asset service provider in El Salvador.
AeroVironment (NASDAQ:AVAV) shares surged about 15% in early trading following the company’s fiscal fourth-quarter results, as investors reacted to stronger-than-expected revenue and earnings, alongside a sharply higher backlog and upbeat defense demand outlook.
AeroVironment (NASDAQ:AVAV) reported Q4 revenue of $641.6 million, a 133% increase from $275.1 million a year earlier and well above Wall Street expectations of about $558 million.
Trillion Energy International Inc. (CSE:TCF, OTCQB:TRLEF, FRA:Z620) announced on Tuesday that it has completed a technical field scouting program across its M47 exploration licence in southeastern Türkiye as it prepares for a planned geophysical data acquisition campaign during the 2026 field season.
The field program, conducted June 6-8, focused on evaluating exploration targets, confirming geological interpretations and refining the design of future seismic surveys. According to the company, the work combined field observations with reviews of historical well data, existing seismic information and regional geological models.
374Water Inc (NASDAQ:SCWO, FRA:8LL) has completed the first phase of a pilot deployment of its mobile AirSCWO waste treatment system in St. Cloud, Minnesota, as the cleantech company continues to evaluate its technology for the destruction of PFAS-containing waste streams.
The project is being carried out under a $600,000 Waste Destruction Services contract with the City of St. Cloud in partnership with Barr Engineering at the city's Nutrient, Energy, and Water Recovery Facility. The pilot is scheduled to continue through mid-September 2026 and is supported by Minnesota's Legislative-Citizen Commission on Minnesota Resources (LCCMR).
Arizona Gold & Silver Inc (TSX-V:AZS, OTCQB:AZASF, FRA:A9J0) has reported results from metallurgical test work at its Philadelphia gold-silver project in Mohave County, Arizona, highlighting strong gold recoveries from both agitation leach and heap leach cyanidation testing.
The company said testing was conducted by Kappes, Cassiday & Associates on a 415.5-kilogram bulk sample collected from a fresh bench cut at the project.
Panmure Liberum has argued that a take-private bid for Sweden's Viva Wine Group lays bare how cheaply the UK's direct-to-consumer wine companies are trading, reiterating buy ratings on both Naked Wines PLC (AIM:WINE, OTCQX:NWINF, FRA:MWJ) and Virgin Wines UK PLC (AIM:VINO).
The broker said the offer for Viva, pitched at 8.5 times forecast 2026 enterprise value to earnings before interest, tax, depreciation and amortisation, highlighted a steep valuation gap with the two London-listed players.
Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) climbed 24% to 2.35p after the precision diagnostics company published two-year data showing its kidney disease test was linked to lasting improvements in patient health.
The study of 2,470 patients with type 2 diabetes and early-stage chronic kidney disease was carried out across two US health systems, Mount Sinai in New York and Wake Forest/Atrium Health in North Carolina.
Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S), the sulfur battery company, has appointed Matthew Wood as chief executive as it shifts from technology development towards commercial scale-up.
He replaces John Wood, who retires from his full-time executive role with immediate effect and steps down from the board after a successful tenure.
Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF, FRA:VD5N) said it is pushing its Paradox Basin project in Utah toward first commercial production after a year in which drilling results and an upgraded reserves report strengthened the investment case, even as revenue from its producing portfolio fell.
The AIM-listed oil and gas group reported 2025 revenue of US$13.9 million, down from US$24.3 million, with gross profit falling to US$2.5 million from US$7.2 million. Net loss narrowed to US$10.8 million from US$19.6 million, helped by the absence of the US$14.5 million impairment charge booked in 2024.
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the erectile dysfunction gel Eroxon, said its experimental treatment for female sexual problems outperformed a placebo in studies.
The company reported results on Tuesday from a home user test and a placebo-controlled study of WSD4000, a topical product aimed at women with impaired sexual response and function.
Environmental Clean Technologies Ltd (ASX:ECT, OTC:ECTHF) has submitted performance data for its Rapid Electrothermal Mineralisation (REM) technology to the United States Environmental Protection Agency, positioning the process as a potential solution for the safe destruction and disposal of PFAS “forever chemicals”.
The submission was made in response to the EPA’s Interim Guidance on the destruction and disposal of PFAS, a consultation opportunity that opens only once every four years. ECT said its submission presents REM against the EPA’s Section 5 evaluation framework, including technology readiness, destruction efficacy, fluorine mass balance, byproduct safety and regulatory relevance.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its ongoing Phase 1b azer-cel trial, marking an early clinical signal in a patient group with limited remaining treatment options.
The first patient in the cohort, who had follicular lymphoma and had previously failed BTKi therapy, achieved a complete response at the Day 28 assessment.
Cyprium Metals Ltd (ASX:CYM, OTCQB:CYPMF) last week outlined strong quarterly progress at its Nifty Copper Complex, with the company remaining on track for first cathode production in the September quarter of 2026.
Executive chairman Matt Fifield said the phase one restart is advancing steadily, with the project now approximately halfway complete in terms of planned hours and budget. He noted that significant progress had been made on heap leach infrastructure, while key capital equipment had begun arriving on site. Fifield described the team as “firing” despite a more complex global operating environment.
Nova Minerals Corp (ASX:NVA, NYSE-A:NVA) high-grade gold concentrate of up to 26.7 g/t from flotation test work on low-grade ore from the Korbel deposit at its Estelle Gold and Critical Minerals Project in Alaska.
During the program, the company highlighted gold recoveries consistently above 95% at Korbel.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has expanded the humanitarian rollout of its nerve repair device, Remplir™, in Ukraine, following growing use of the product for severe peripheral nerve injuries caused by the ongoing conflict.
The regenerative medicine company said additional devices were now being shipped to Ukraine through a coordinated philanthropic initiative, after an initial deployment in April 2025 supported battlefield trauma programs.